On Tuesday, Newcastle Investment Corp. (NYSE:NCT)’s shares declined -4.60% to $4.15.
Newcastle Investment Corp. (NCT) declared that its Board of Directors has declared a cash dividend on its common stock of $0.12 per share for the quarter ending September 30, 2015. The dividend is payable on October 30, 2015 to shareholders of record on October 1, 2015.
The Board of Directors also declared dividends on the Company’s preferred stock for the period starting August 1, 2015 and ending October 31, 2015. The dividends are payable on October 30, 2015 to shareholders of record on October 1, 2015. The Company will pay dividends of $0.609375, $0.503125 and $0.523438 per share on the 9.750% Series B, 8.050% Series C and 8.375% Series D preferred stock, respectively.
Newcastle Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in and manages real estate related and other investments, counting senior housing properties; debt investments financed with collateralized debt obligations; other debt investments; and investments in golf courses and facilities.
Canadian Solar Inc. (NASDAQ:CSIQ)’s shares gained 0.89% to $15.86.
Canadian Solar Inc. (CSIQ), one of the world’s largest solar power companies, declared it has released its 2014 Corporate Social Responsibility (CSR) report.
The CSR report shows our commitment to sustainable social and environmental development. Our 2014 CSR report strictly follows the international standard for sustainability reports, the Global Reporting Initiative (GRI) G4, and demonstrates Canadian Solar’s firm commitment to making the difference.
While the bulk of the report reviews Canadian Solar’s social, economic and environmental sustainability efforts over the last few years, it is also a forward-looking document.
Canadian Solar Inc., together with its auxiliaries, designs, develops, manufactures, and sells solar wafers, cells, and solar power products worldwide. The company operates in two segments, Module and Energy.
At the end of Tuesday’s trade, AstraZeneca plc (ADR) (NYSE:AZN)‘s shares dipped -0.41% to $31.28.
AstraZeneca (AZN) declared that BRILINTA® (ticagrelor) 60-mg tablets are now accessible in US pharmacies. On September 3, 2015, the US Food and Drug Administration (FDA) approved a new 60-mg dosage strength for BRILINTA to be used in patients with a history of heart attack beyond the first year. BRILINTA is approved to reduce the rate of cardiovascular (CV) death, myocardial infarction ([MI], also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, BRILINTA is superior to clopidogrel. BRILINTA is the first and only FDA approved oral antiplatelet to demonstrate superior reductions in CV death vs clopidogrel at 12 months.
The dosing of BRILINTA in the administration of ACS is 90 mg twice daily during the first year after an ACS event. After one year, patients with a history of heart attack can now be treated with 60 mg twice daily. BRILINTA must be used with a daily maintenance dose of aspirin of 75-100mg.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products comprise Crestor for dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium to treat acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients.
Duke Realty Corp (NYSE:DRE), ended its Tuesday’s trading session with 1.38% gain, and closed at $19.12.
Duke Realty Corporation (DRE), will hold its quarterly conference call to talk about third quarter results on Thursday, October 29th, 2015, at 3:00 p.m. Eastern Time. Duke Realty will release its Third Quarter 2015 earnings on Wednesday, October 28th, after market close.
The public may access the conference through a live audio webcast accessible on the investor relations section of Duke Realty’s website at www.dukerealty.com. Supplemental materials will be posted to the investor relations section of the Company’s website preceding to the conference call. Institutional investors can also access the conference via Thomson Reuters’ password-protected event administration site, StreetEvents (www.streetevents.com). Shortly after the conclusion of the conference call, investors can access a replay of the webcast on the Company’s website.
Duke Realty owns and operates more than 142.3 million rentable square feet of industrial and office, counting medical office, space in 22 major metropolitan areas. Duke Realty is publicly traded on the NYSE under the symbol DRE and is listed on the S&P MidCap 400 Index.
Duke Realty Corporation is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It offers a single point of responsibility for all aspects of a project, counting leasing, asset administration, construction and development. The firm primarily invests in commercial real estate sector.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
